Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study
# Background Prescription drug insurance in Canada is constituted of a patchwork of public and private insurance plans. The type of drug insurance may have a negative impact on access to treatment for patients covered by public plans compared with private plans. # Objectives In patients with psoria...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2025-02-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.127820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | # Background
Prescription drug insurance in Canada is constituted of a patchwork of public and private insurance plans. The type of drug insurance may have a negative impact on access to treatment for patients covered by public plans compared with private plans.
# Objectives
In patients with psoriasis treated with advanced therapy in public vs private drug insurance groups, we compared: (1) psoriasis severity scores when an advanced therapy was prescribed, (2) psoriasis severity scores at follow-up, (3) treatment response, and (4) delay between prescription and first dose of advanced therapy.
# Methods
This unicentric, retrospective cohort study included patients suffering from psoriasis treated by advanced therapy, dermatologist-prescribed between September 2015 and August 2019, in a tertiary academic care center in Québec City, Canada. Data were collected from medical records.
# Results
Patients treated with an advanced therapy for psoriasis covered under the provincial public drug insurance plan (n = 78) and under a private drug plan (n = 93) did not differ regarding the studied outcomes. Patients’ characteristics differed between groups. Patients in the public group were older (_P_ < .0001), more socioeconomically deprived (_P_ < .05), and more likely to benefit from compassion from the industry to access a prescribed medication free of charge (_P_ < .0001) compared with patients from the privately insured group.
# Discussion
The high prevalence of compassionate programs from the industry in the public insurance group (42% vs 14%), and the high prevalence of psoriasis on difficult-to-treat areas (face, genitalia, and/or palmoplantar areas) in our cohort (85.4%) may mask differences in access to advanced therapy between the two groups.
# Conclusions
Prescribers of advanced therapy can be reassured, as we found no inequality in access or care based on patients’ drug insurance coverage. |
|---|---|
| ISSN: | 2327-2236 |